Stock Markets March 10, 2026

Smile Doctors Weighs $2 Billion Refinance to Lower Borrowing Costs

Dental services chain explores a sale of existing loans into the US leveraged loan market with Barclays advising on the potential deal

By Priya Menon
Smile Doctors Weighs $2 Billion Refinance to Lower Borrowing Costs

Smile Doctors LLC is engaged in preliminary talks to refinance roughly $2 billion of debt, aiming to bring down interest expenses by shifting loans held by private creditors into the broader US leveraged loan market. Barclays Plc has been retained to lead the potential transaction, which remains at an early stage and may not materialize.

Key Points

  • Smile Doctors is in early-stage discussions to refinance about $2 billion of debt to lower interest expenses.
  • Barclays Plc has been retained to lead a potential offering into the US leveraged loan market.
  • Current loans are held by private lenders such as Blackstone Inc. and Antares, and carry a spread of 5.75 percentage points over the Fed's SOFR benchmark; proceeds originally funded a THL investment in January 2022.

Smile Doctors LLC is privately pursuing options to refinance about $2 billion of outstanding debt, according to people familiar with the discussions. The company is seeking lower borrowing costs by moving existing loans into the US leveraged loan market, with Barclays Plc appointed to run the potential transaction.

The dental-services operator currently has debt held by a number of private lenders, among them Blackstone Inc. and Antares. Those loans presently carry an interest spread of 5.75 percentage points above the Federal Reserve's secured overnight financing rate benchmark. Company representatives believe that placing the loan with a wider set of investors could reduce the effective cost of borrowing.

Proceeds from the debt now being considered for refinancing were used to finance an investment by THL in January 2022. Prior to that, Linden took a majority stake in Smile Doctors in 2017.

People familiar with the matter emphasize that conversations are in early stages and that a transaction may ultimately not occur. No additional details on timing, structure or pricing have been disclosed in the discussions reported so far.


Context and market focus

This effort would route existing private loans into the syndicated US leveraged loan market, a venue where collateralized debt obligations and institutional investors commonly purchase loans. The goal stated by those involved is to reduce the company's borrowing costs by expanding the investor base for the debt.

What is known

  • Smile Doctors is considering refinancing approximately $2 billion of debt.
  • Barclays Plc has been appointed to lead potential activity in the US leveraged loan market.
  • Existing lenders include Blackstone Inc. and Antares, and the loans carry a spread of 5.75 percentage points over the Fed's SOFR benchmark.

Deal status

Those familiar with the conversations caution that the process is exploratory. There has been no confirmation that terms have been agreed or that financing will proceed. The company and advisors are, by these accounts, examining whether a broader sale of the loan can deliver lower interest costs.

Risks

  • The refinancing discussions are preliminary and may not result in a transaction - this creates uncertainty for creditors and potential investors in the leveraged loan market.
  • If a sale to a wider investor base does not yield lower borrowing costs, the company may remain exposed to higher interest expense, affecting financial flexibility in the healthcare and dental services sector.
  • Because specific timing, structure and pricing have not been disclosed, market participants face incomplete information when assessing impacts on lenders and private equity stakeholders.

More from Stock Markets

SUMA Acquisition Prices $150 Million IPO; Units to Begin Nasdaq Trading March 11, 2026 Mar 10, 2026 Planet Labs widens Middle East imagery delay to 14 days to limit adversarial use Mar 10, 2026 Thomas Mazloum Elevated to Chair of Disney Experiences as Josh D'Amaro Prepares to Become CEO Mar 10, 2026 Microsoft Files Brief Backing Anthropic’s Bid to Halt DOD Supply-Chain Designation Mar 10, 2026 MDA Space Files for $300 Million U.S. IPO, Eyes New York Listing Mar 10, 2026